← All diseases Cancer

Mesothelioma

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchHighest level of evidence only (25)Meta-analysis (7)Treatment guideline (2)Systematic review (9)Phase 3 study (5)Randomized trial (2)Clinical trial (594)Review article (165)Early study (phase 1 or 2) (48)Single patient description (165)Laboratory or animal study (30)Commentary or editorial (70)Concerns have been raised (1)Retracted publication (1) Studies currently recruiting participants only (33)

Filter

Publications and studies (1696)

• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. PF-06952229 Treatment in Adult Patients with Advanced Solid Tumors (2024-06-26) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Ga-68 FAPI PET Before Immunotherapy (2024-06-11) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. PIPAC With Nab-paclitaxel and Cisplatin in Peritoneal Carcinomatosis (2024-05-24) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma (2024-05-23) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (2024-05-21) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Study of Cadonilimab Combined With Chemotherapy in Recurrent/Refractory Pleural Mesothelioma (2024-05-16) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Evaluation of Response by FLT PET in Mesothelioma (2024-05-16) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma (2024-05-14) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. eRapid: Online Symptom Reporting in Lung Cancer (2024-05-08) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer (2024-04-25) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors (2024-04-01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition (2024-03-15) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (2024-02-29) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Treatment of Pleural Carcinosis or Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration (2024-02-28) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma (2024-02-21) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants (2024-02-20) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma (2024-02-07) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma (2024-02-02) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin (2024-02-02) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Molecular, Pathologic Intra Tumoral Heterogeneity in Malignant Pleural Mesothelioma (2024-02-01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Dendritic Cell Immunotherapy for Mesothelioma (2024-02-01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma (2024-01-03) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Occupational asbestos exposure and ovarian cancer: updated systematic review. (2023/12/30) ♡
• Asbestos burden in lungs of non-occupationally exposed women from Broni (Pavia, Italy): a postmortem SEM-EDS study. (2023/12/30) ♡
• Impact of guideline therapy on survival of patients with stage I-III epithelioid mesothelioma. (2023/12/30) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Reforming primary palliative care: a call to arms. (2023/12/28) ♡
• Reflecting real-world patients with mesothelioma in research: an interim report of baseline characteristics from the ASSESS-meso cohort. (2023/12/27) ♡
• Does subtyping of high-grade pulmonary neuroendocrine carcinomas have an impact on therapy selection? (2023/12/26) ♡
• Occupational and Environmental Asbestos Exposure and Survival of Patients with Asbestos-Related Cancer: A Follow-Up Study on Patients with Malignant Mesothelioma and Asbestos-Related Lung Cancer in Korea. (2023/12/25) ♡
• Validation of Inflammatory Prognostic Biomarkers in Pleural Mesothelioma. (2023/12/24) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Complete clinical remission of malignant peritoneal mesothelioma with systemic pemetrexed and bevacizumab in a patient with a BAP1 mutation. (2023/12/23) ♡
• Serum Calretinin and Genetic Variability as a Prognostic and Predictive Factor in Malignant Mesothelioma. (2023/12/22) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Efficacy and safety profile of combining antiangiogenic agents with chemotherapy in patients with advanced malignant pleural mesothelioma: A systematic review and meta-analysis of randomized controlled trials. (2023/12/21) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Lichenoid drug reaction after ipilimumab/nivolumab combination therapy: A case report. (2023/12/20) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies. (2023/12/20) ♡
• Short-Term Outcomes of COVID-19 Pandemic on Non-Small Cell Lung Cancer Screening and Management. (2023/12/20) ♡
• Tasks and Experiences of the Prospective, Longitudinal, Multicenter MoMar (Molecular Markers) Study for the Early Detection of Mesothelioma in Individuals Formerly Exposed to Asbestos Using Liquid Biopsies. (2023/12/18) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Malignant pleural mesothelioma mimics thoracic empyema: A case report. (2023/12/16) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. A 51-Year-Old Woman with Advanced Peritoneal Mesothelioma and Stage 3b Chronic Kidney Disease Treated with Cytoreductive Surgery and Bidirectional Intraperitoneal Cisplatin and Ifosfamide Chemotherapy: A Case Report. (2023/12/14) ♡
• Diagnostic value of computed tomography and magnetic resonance imaging in ovarian malignant mesothelioma. (2023/12/14) ♡
• Second annual report from the ISSPP PIPAC database. (2023/12/13) ♡
• [Chinese expert consensus on treatment of malignant pleural effusion (2023 Edition)]. (2023/12/12) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The Current Treatment Landscape of Malignant Pleural Mesothelioma and Future Directions. (2023/12/12) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study. (2023/12/11) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Multimodality local consolidative treatment versus conventional care of advanced lung cancer after first-line systemic anti-cancer treatment: study protocol for the RAMON multicentre randomised controlled trial with an internal pilot. (2023/12/10) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy. (2023/12/10) ♡
• [Application and evaluation of EFEMP1 in differential diagnosis of malignant mesothelioma and poorly differentiated adenocarcinoma]. (2023/12/08) ♡
• [Malignant mesothelioma in Colombia: burden of disease, overview, and subnational sociodemographic index, 2015-2020Malignant mesothelioma in Colombia: disease burden, overview and subnational sociodemographic index, 2015-2020]. (2023/12/08) ♡
• LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study. (2023/12/07) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Clinical Next Generation Sequencing Application in Mesothelioma: Finding a Golden Needle in the Haystack. (2023/12/06) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.